Cargando…
Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
PURPOSE OF REVIEW: We summarize the best evidence for statins in the prevention and treatment of heart failure. RECENT FINDINGS: In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart f...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660504/ https://www.ncbi.nlm.nih.gov/pubmed/31350612 http://dx.doi.org/10.1007/s11883-019-0800-z |
_version_ | 1783439312699785216 |
---|---|
author | Lee, Matthew M. Y. Sattar, Naveed McMurray, John J. V. Packard, Chris J. |
author_facet | Lee, Matthew M. Y. Sattar, Naveed McMurray, John J. V. Packard, Chris J. |
author_sort | Lee, Matthew M. Y. |
collection | PubMed |
description | PURPOSE OF REVIEW: We summarize the best evidence for statins in the prevention and treatment of heart failure. RECENT FINDINGS: In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart failure—mainly by preventing myocardial infarction although an additional benefit from reducing myocardial ischemia cannot be excluded. However, in patients with established heart failure, statins do not reduce the risk of cardiovascular death, which is mainly caused by pump failure and ventricular arrhythmias. Retrospective analyses, however, suggest that statins may reduce the rate of heart failure hospitalization and atherosclerotic events (which are proportionately much less common in these patients than heart failure hospitalization or death). SUMMARY: Statin therapy should probably be continued in patients with coronary artery disease developing heart failure, although the weak evidence and small benefit may not justify the use of this treatment in very elderly patients with a short life expectancy and in which polypharmacy is a problem. |
format | Online Article Text |
id | pubmed-6660504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-66605042019-08-07 Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence Lee, Matthew M. Y. Sattar, Naveed McMurray, John J. V. Packard, Chris J. Curr Atheroscler Rep Statin Drugs (M. Tikkanen, Section Editor) PURPOSE OF REVIEW: We summarize the best evidence for statins in the prevention and treatment of heart failure. RECENT FINDINGS: In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart failure—mainly by preventing myocardial infarction although an additional benefit from reducing myocardial ischemia cannot be excluded. However, in patients with established heart failure, statins do not reduce the risk of cardiovascular death, which is mainly caused by pump failure and ventricular arrhythmias. Retrospective analyses, however, suggest that statins may reduce the rate of heart failure hospitalization and atherosclerotic events (which are proportionately much less common in these patients than heart failure hospitalization or death). SUMMARY: Statin therapy should probably be continued in patients with coronary artery disease developing heart failure, although the weak evidence and small benefit may not justify the use of this treatment in very elderly patients with a short life expectancy and in which polypharmacy is a problem. Springer US 2019-07-27 2019 /pmc/articles/PMC6660504/ /pubmed/31350612 http://dx.doi.org/10.1007/s11883-019-0800-z Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Statin Drugs (M. Tikkanen, Section Editor) Lee, Matthew M. Y. Sattar, Naveed McMurray, John J. V. Packard, Chris J. Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence |
title | Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence |
title_full | Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence |
title_fullStr | Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence |
title_full_unstemmed | Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence |
title_short | Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence |
title_sort | statins in the prevention and treatment of heart failure: a review of the evidence |
topic | Statin Drugs (M. Tikkanen, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660504/ https://www.ncbi.nlm.nih.gov/pubmed/31350612 http://dx.doi.org/10.1007/s11883-019-0800-z |
work_keys_str_mv | AT leematthewmy statinsinthepreventionandtreatmentofheartfailureareviewoftheevidence AT sattarnaveed statinsinthepreventionandtreatmentofheartfailureareviewoftheevidence AT mcmurrayjohnjv statinsinthepreventionandtreatmentofheartfailureareviewoftheevidence AT packardchrisj statinsinthepreventionandtreatmentofheartfailureareviewoftheevidence |